Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 72603-875

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 72603-875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Vte Risk With Yasmin Relative To Lng-containing Cocs (adjusted Risk#) (Drospirenone Fig1)

A logarithmic scale graph comparing the risk ratios of venous thromboembolism (VTE) with Yasmin relative to LNG-containing combined oral contraceptives (COCs). The graph lists multiple studies grouped by study type: prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only. Each study shows a point estimate with confidence intervals indicating the risk ratio, with a reference line at 1 for no increased risk.*

FDA Label Image

Figure 2: Likelihood Of Developing A Vte (Drospirenone Fig2)

A horizontal bar chart illustrating the likelihood of developing a venous thromboembolism (VTE) among different groups of women. It compares non-pregnant non-COC users, combined oral contraceptive (COC) users, pregnant women, and postpartum women (12 weeks only), showing the estimated number of women developing a blood clot per 10,000 women years. The likelihood ranges from 1-5 for non-pregnant non-COC users, 3-9 for COC users, 5-20 for pregnancy, and 40-65 for postpartum.*

FDA Label Image

Figure 3: Relative Studies Of Risk Of Breast Cancer With Combined Oral Contraceptives (Drospirenone Fig3)

A forest plot displaying effect estimates (OR, RR, HR) and confidence intervals from several studies comparing Ever COC use vs. Never COC use and Current COC use vs. Never-Use. The plot includes study names, years, and effect estimate values with confidence intervals, showing variability in effect sizes across different studies.*

FDA Label Image

Figure 4 (Drospirenone Fig4)

An illustration showing a vertical arrow labeled 'Fewer Pregnancies' at the top and 'More Pregnancies' at the bottom, with corresponding pregnancy rates per 100 women per year alongside. It categorizes birth control methods by effectiveness: implants, injections, intrauterine devices, and sterilization at the top (fewer than 1 pregnancy); birth control pills, skin patch, and vaginal ring next; condoms and diaphragm in the middle; no sex during fertile days, spermicide, and withdrawal below that; and no birth control at the bottom (85 or more pregnancies).*

FDA Label Image

Figure 5 (Drospirenone Fig5)

Diagram of a 4-week pill organizer for Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.02 mg. The layout includes rows for Sunday through Saturday, guiding users to take pills daily from Week 1 through Week 4, with directional arrows indicating the sequence.*

FDA Label Image

Figure 6 (Drospirenone Fig6)

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman years among four groups: non-pregnant non-COC users, COC users, pregnant women, and postpartum women (12 weeks only). The chart provides ranges for each group, with the highest range observed in postpartum women, followed by pregnancy, COC users, and non-pregnant non-COC users.*

FDA Label Image

Package Label-principal Display Panel (3 mg/0.02 mg Pouch Label)

Packaging label for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, KIT dosage form. The label includes the NDC 72603-875-01 and states that the kit contains one blister pack of 28 tablets. It is labeled Rx only and manufactured by NorthStar Rx LLC. The label also notes storage conditions and directs users to patient information included in the pouch.*

FDA Label Image

Package Label-principal Display Panel (3 mg/0.02 mg Pouch Carton)

Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, kit carton label by NorthStar Rx LLC. The packaging contains 3 pouches, each with one blister pack of 28 tablets. The label includes directions on dosage, storage, and dispensing, highlighting that this oral contraceptive does not protect against HIV or other sexually transmitted diseases. Manufactured by Aurobindo Pharma Limited in India.*

FDA Label Image

Chemical Structure (Drospirenone Str)

Chemical structure diagrams of Drospirenone and Ethinyl Estradiol, the active ingredients in the Drospirenone and Ethinyl Estradiol human prescription drug kit by NorthStar Rx LLC. The image shows labeled molecular structures for each compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.